Skip to main content

Fiscal Wizard · Single-issue tearsheet

WST / Aug 13, 2026 Run #13849

WST

West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Composite verdict

B 62.1 / 100
Bullish setup · Reversal 9 drivers · 3 gates blocking
  • Accumulation/Distribution Line
  • MACD Signal Cross
  • Declining Volume
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 4th of 8 in Medical Instruments & Supplies

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 23 signals0% Bear
Momentum Bullish 77Mean-reversion Bullish 66

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -85%
Asset value $45.13Earnings power value $82.02Price $352.29

Priced above its no-growth earnings power value ($82.02/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Weak

27.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion 90
PEGY 0
Asset Turnover 81
PEG 0
Return on Assets 68
Margin of Safety 0

Technicals Bullish

96.6 / 100

Bullish setup leads (Accumulation/Distribution Line, MACD Signal Cross, Declining Volume); bears gated by guards. · 44 signals shown.

Strongest
Weakest
MACD Signal Cross 88
Accumulation/Distribution Line 88
Declining Volume 84

Risk Gates

3 blocking 5 caution

3 guards active, 19 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for WST.